(HealthDay)—Fragmin (dalteparin sodium) injection has been granted the first approval for subcutaneous use in preventing recurrence of symptomatic venous thromboembolism (VTE) in children aged 1 month or older, the U.S. Food and Drug Administration announced.

Source link